Stocks and Investing
Stocks and Investing
Tue, February 6, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, February 5, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mohit Bansal Maintained (ABBV) at Buy with Increased Target to $200 on, Feb 5th, 2024
Mohit Bansal of Wells Fargo, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $180 to $200 on, Feb 5th, 2024.
Mohit has made no other calls on ABBV in the last 4 months.
There are 5 other peers that have a rating on ABBV. Out of the 5 peers that are also analyzing ABBV, 2 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Rajesh Kumar of "HSBC" Downgraded from Strong Buy to Hold and Decreased Target to $156 on, Monday, December 18th, 2023
- James Shin of "Deutsche Bank" Initiated at Hold and Held Target at $150 on, Thursday, November 9th, 2023
These are the ratings of the 3 analyists that currently disagree with Mohit
- Tim Lugo of "William Blair" Upgraded from Hold to Buy on, Monday, January 29th, 2024
- Chris Shibutani of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $173 on, Monday, December 11th, 2023
- Terence Flynn of "Morgan Stanley" Maintained at Buy with Increased Target to $196 on, Monday, October 30th, 2023
Contributing Sources